MRK Revenue
Revenue at Merck & Co. rose to $65.0B in fiscal 2025, the highest in the 5 years reported, from $64.2B in 2024.
Total revenues as filed (us-gaap fallback chain; for financials, net revenue or net interest income). Source tag recorded per name.
SOURCE: us-gaap:Revenues · EDGAR CompanyFacts · CIK 310158 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $65.0B | +$843M |
| FY2024 | $64.2B | +$4.1B |
| FY2023 | $60.1B | +$832M |
| FY2022 | $59.3B | +$10.6B |
| FY2021 | $48.7B | — |
Cross-checks touching this measure FROM THE FILING REVIEW
✓ MATCHEStotal revenue
Every quoted figure reconciles to the filed lines: $ 65,011 against total revenues; $ 64,168 against total revenues; $ 60,115 against total revenues.
FY2025 10-K · FULL RECONCILIATION →◐ PARTLYsales growth
2 of 3 quoted figures reconcile ($65.0 billion against total revenues; 1% against total revenues); 2% does not map to a filed line on this page — carried as partly supported.
FY2025 10-K · FULL RECONCILIATION →◐ WATCHReceivables pace
Days sales outstanding moved +7.6 days. Carried as watch; this page verifies no stated cause.
FY2025 10-K · FULL RECONCILIATION →◐ WATCHInventory vs revenue pace
Inventory grew +7.7pp faster than revenue. Carried as watch (7pp threshold).
FY2025 10-K · FULL RECONCILIATION →More SAME DATA, OTHER VIEWS
Revenue across coverage → · MRK company view →
Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.